GMAB vs RPRX

Genmab A/S and Royalty Pharma plc, both Healthcare

Royalty Pharma plc is the larger company at $39B against $33B. On trailing earnings GMAB has the lower P/E of the two, 33.2 against 44.9. RPRX keeps 57 cents of operating profit from each dollar of sales against 29 for GMAB, and GMAB grew sales faster over the last year, +19% against +11%. Over the past year RPRX returned +81% against +75% for GMAB.

Genmab A/S and Royalty Pharma plc compared on valuation multiples, growth, margins and return
FigureGMABRPRX
Last close$50.98$68.68
Market cap$33B$39B
Trailing P/E33.244.9
Revenue growth+19%+11%
Operating margin29%57%
Net margin26%26%
Free cash flow yield3.5%n/a
Net cash$3.6B net debt$8.0B net debt
Insiders, 12 monthsn/asold $93M net
1-year return+75%+81%
5-year return+9.6%+95%

Figures from SEC filings and end-of-day closes. Highlighting marks the higher number in each row, nothing more.

Genmab A/S

Revenue of $2.1B in the quarter to Dec 31, 2025, net income $432M.

Royalty Pharma plc

Revenue of $690M in the quarter to Sep 30, 2026, net income $145M. Its largest reported line is Financial Royalty Assets, 95% of the disclosed total.

Open these two in the interactive comparison to add more names, change the period or see the correlation.